Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.96%
#2 aelf aelf +23.43%
#3 Bitway Bitway +23.30%
#4 Pons Pons +14.07%
#5 Starpower Starpower +13.59%
#6 Decred Decred +13.55%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +12.19%
#8 TRIA TRIA +10.92%
#9 AtomOne AtomOne +9.50%
#10 DAPPOS DAPPOS +8.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Vectorite Biomedical Inc. Vectorite Biomedical Inc.

Vectorite Biomedical Inc.

4170
Rank in Stocks #30382
Vectorite Biomedical Inc., established in 1993 and based in New Taipei City,... Vectorite Biomedical Inc., established in 1993 and based in New Taipei City, Taiwan, is a biotechnology firm dedicated to research and development activities globally, including a strong presence in its home country. The company's operations encompass the manufacturing of specialized cell preparation products, in addition to providing full-spectrum services for the collection, processing, and secure storage management of immune cells. These advanced cellular preparations are vital for applications in the medical fields of infectious diseases, inflammatory conditions, and various oncological and tumor-related illnesses.
Share Price
$0.38953809
Market Cap
$17.05M
Change (1 day)
-0.81%
Change (1 year)
-9.39%
Country
TW
Trade Vectorite Biomedical Inc. (4170)

Category

Healthcare
Revenue for Vectorite Biomedical Inc. (4170)
Revenue in Aug 2026 TTM: 0
According to Vectorite Biomedical Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vectorite Biomedical Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR